I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

David Liu Biography and Net Worth

Insider of Protagonist Therapeutics

Dr. Liu has served as the Company’s Chief Scientific Officer since May 2013 and served as Chief Scientific Officer and Head of Research and Development since February 2016. In connection with a title change effective January 1, 2020, Dr. Liu now serves as the Company’s Chief Scientific Officer and Head of Discovery & Pre-Clinical Development. Prior to Protagonist, Dr. Liu was the Chief Operating Officer and a cofounder of Trenovus, Inc., from 2010 to 2012. Prior to Trenovus, Dr. Liu was Vice President of Research at FibroGen Inc., from 2002 to 2010. Prior to FibroGen, Dr. Liu served as Director of Inflammation Research at Scios, Inc., now part of Johnson & Johnson, from 1992 to 2002. Dr. Liu held a position as an academic researcher at Brigham and Women’s Hospital, Harvard Medical School and was Instructor and Assistant Professor in the Department of Medicine, Harvard Medical School, from 1976 to 1986. Dr. Liu received his Ph.D. in microbiology and immunology from Michigan State University, and his B.S. in Chemistry from The University of Chicago.

What is David Y. Liu's net worth?: The estimated net worth of David Y. Liu is at least $1.54 million as of February 6th, 2019. Dr. Liu owns 37,007 shares of Protagonist Therapeutics stock worth more than $1,535,420 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Liu may own. Learn More about David Y. Liu's net worth.
How do I contact David Y. Liu?: The corporate mailing address for Dr. Liu and other Protagonist Therapeutics executives is 7707 GATEWAY BOULEVARD SUITE 140, NEWARK CA, 94560. Protagonist Therapeutics can also be reached via phone at (510) 474-0170 and via email at [email protected]. Learn More on David Y. Liu's contact information.
Has David Y. Liu been buying or selling shares of Protagonist Therapeutics?: David Y. Liu has not been actively trading shares of Protagonist Therapeutics during the last quarter. Learn More on David Y. Liu's trading history.
Who are Protagonist Therapeutics' active insiders?: Protagonist Therapeutics' insider roster includes Asif Ali (EVP, CFO), Suneel Gupta (Chief Development Officer), David Liu (Insider), Dinsesh Patel (CEO), and William Waddill (Director). Learn More on Protagonist Therapeutics' active insiders.
Are insiders buying or selling shares of Protagonist Therapeutics?: In the last year, insiders at the sold shares 15 times. They sold a total of 371,523 shares worth more than $15,191,715.79. The most recent insider tranaction occured on November, 27th when insider Arturo Md Molina sold 26,000 shares worth more than $1,162,200.00. Insiders at Protagonist Therapeutics own 5.4% of the company. Learn More about insider trades at Protagonist Therapeutics.
Information on this page was last updated on 11/27/2024.

David Y. Liu Insider Trading History at Protagonist Therapeutics

David Y. Liu Buying and Selling Activity at Protagonist Therapeutics

Protagonist Therapeutics Company Overview

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Today's Range

Now: $41.49

$38.91

$41.68

50 Day Range

MA: $44.02

$38.65

$48.43

2 Week Range

Now: $41.49

$20.88

$48.89

Volume

2,360,707 shs

Average Volume

748,240 shs

Market Capitalization

$2.47 billion

P/E Ratio

15.60

Dividend Yield

N/A

Beta

2.18

I was wrong. Dead wrong.

From Porter & Company | Ad